Hach Company manufactures and distributes analytical instruments and reagents to monitor and test the quality of water. Hach products feature complete, easy-to-use methods, high quality prepared reagents, and life-time technical support. Hach Company's headquarters in Loveland, Colorado supports research, development, manufacturing and corporate activities.
Eurofins Scientific was founded in 1987 to market the SNIF-NMR technology, a patented analytical method used to verify the origin and purity of several types of food and beverages in cases where traditional testing methods would fail to detect a sophisticated fraud. Within a 20-year period, the Group has grown from a start-up company with 12 employees to become an international network of over 150 laboratories located in Europe, the USA, Asia and South-America employing about 7,000 staff. Eurofins' history can be divided up into four distinct phases:
Based in Chelmsford, Massachusetts, ESA is a privately held analytical instrumentation company that has enjoyed steady growth and profitability since 1972. The company manufactures innovative analytical instruments and provides complete support for a full line of chromatographic separation systems. By using basic electrochemistry to detect harmful materials in the environment, ESA has developed inventions and technologies that have played a significant role in safeguarding the health of people for more than 30 years.
EnviroLogix provides the following warranty with all its products: EnviroLogix Inc. ("EnviroLogix") warrants the products sold hereunder ("the Products") against defects in materials and workmanship when used in accordance with the applicable instructions for a period of one year from the date of shipment of the products or if shorter, for a period not to extend beyond a product's printed expiration date. If the Products do not conform to this Limited Warranty and the customer notifies EnviroLogix in writing of such defects during the warranty period, including an offer by the customer to return the Products to EnviroLogix for evaluation, EnviroLogix will repair or replace, at its option, any product or part thereof that proves defective in materials or workmanship within the warranty period. EnviroLogix MAKES NO (ANY) OTHER WARRANTIES, EXPRESSED OR IMPLIED, INCLUDING BUT NOT LIMITED TO ANY IMPLIED WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. The warranty provided herein and the data, specifications and descriptions of EnviroLogix products appearing in EnviroLogix published catalogues and product literature are EnviroLogix' sole representations concerning the Products and warranty. No other statements or representations, written or oral, by EnviroLogix' employees, agents or representatives, except written statements signed by a duly authorized officer of EnviroLogix Inc., are authorized; they should not be relied upon by the customer and are not a part of the contract of sale or of this warranty. EnviroLogix does not warrant against damages or defects arising in shipping or handling, or out of accident or improper or abnormal use of the Products; against defects in products or components not manufactured by EnviroLogix, or against damages resulting from such non-EnviroLogix made products or components. EnviroLogix passes on to customer the warranty it received (if any) from the maker thereof of such non-EnviroLogix made products or components. This warranty also does not apply to Products to which changes or modifications have been made or attempted by persons other than pursuant to written authorization by EnviroLogix. THIS WARRANTY IS EXCLUSIVE. The sole and exclusive obligation of EnviroLogix shall be to repair or replace the defective Products in the manner and for the period provided above. EnviroLogix shall not have any other obligation with respect to the Products or any part thereof, whether based on contract, tort, strict liability or otherwise. Under no circumstances, whether based on this Limited Warranty or otherwise, shall EnviroLogix be liable for incidental, special, or consequential damages. This Limited Warranty states the entire obligation of EnviroLogix with respect to the Products. If any part of this Limited Warranty is determined to be void or illegal, the remainder shall remain in full force and effect.
Quintiles helps improve healthcare worldwide by providing a broad range of professional services, information and partnering solutions to the pharmaceutical, biotechnology and healthcare industries. Headquartered near Research Triangle Park, North Carolina, Quintiles has offices in 50 countries and is the world's leading pharmaceutical services organization.
Celsis International plc is a world leading provider of innovative life science products and laboratory services to the pharmaceutical, biopharmaceutical, and consumer products industries through its three business areas; rapid detection, analytical and drug development services and ADME-Tox in vitro technologies. The company is listed on the London Stock Exchange (CEL.L). Each division of Celsis International plc has the capacity to deliver substantial time and cost savings to its customers, in addition to ensuring product quality and safety for consumers. Celsis Rapid Detection division utilises proprietary enzyme technology to develop and supply diagnostic testing instruments and consumables for the rapid detection of microbial contamination in pharmaceutical and consumer products. These rapid testing systems provide significant economic value by reducing the time it takes to test and release raw materials, in process and finished goods to market. Celsis Analytical Services division provides cost effective outsourced laboratory testing services to pharmaceutical and biopharmaceutical companies. Its comprehensive service offerings include a full spectrum of laboratory services from drug development and discovery to analytical chemistry and biological sciences to stability storage and testing. Celsis In Vitro Technologies (Celsis IVT) employs proprietary expertise in hepatocyte (liver cell) technology to supply in vitro testing products to the pharmaceutical and biotechnology industries. Celsis IVT's consumable testing products screen drug compounds for liver toxicity early in the drug discovery process, thereby reducing the time and cost of further development or trial on those compounds which will not be properly metabolised by the human liver. Please contact Jenny Woolway at jwoolway@celsis.com for corporate information.
Headquartered in Raleigh, N.C., LipoScience develops and markets new clinical applications of NMR spectroscopy in the areas of cardiovascular disease and metabolic disorders. Its flagship product, the NMR LipoProfile blood test, was introduced for clinical research in 1997 and for use in patient care in 1999. Results previously reported from the Cardiovascular Health Study(1), Healthy Women Study(2) and PLAC-1(3), among others, have all shown that numbers of atherogenic LDL particles to be more predictive of coronary heart disease events than LDL cholesterol. (1) Kuller LH, Arnold A, Tracy R, et al. Nuclear Magnetic Resonance (NMR) spectroscopy of lipoproteins and risk of coronary heart disease in the cardiovascular health study.
PharmaNet offers all the clinical development services traditionally associated with conducting Phase II-IV programs. A key differentiating factor of PharmaNet is that in every program we conduct, PharmaNet provides an unrivaled combination of experienced project-management teams, senior management oversight, and an exclusive approach to building relationships with sponsors.
Immucor, Inc. (Immucor) develops, manufactures and sells a complete line of reagents and automated systems used primarily by hospitals, clinical laboratories and blood banks in a number of tests performed to detect and identify certain properties of the cell and serum components of human blood prior to blood transfusion. During the fiscal year ended May 31, 2008 (fiscal 2008), the Company launched the Echo instrument. The Echo has many of the features of the Galileo, the Company’s automated assay instrument which caters to customers, including a test menu. As of May 31, 2008, the Company had received orders for a total of 257 Echo instruments worldwide, including 56 in Europe, 196 in North America and five in Japan, and approximately 91 of these Echo instruments were generating reagent revenues. In August 2008, the Company closed its acquisition of BioArray Solutions Ltd.
Medpace is a contract research organization, based in Cincinnati, Ohio, that manages the clinical trial process for pharmaceutical and biotechnology companies. Over the last 15 years, Medpace has provided seamless drug development to its clients. We have steadily expanded operations to almost 40 countries. We are currently seeking a Medical Director specializing in Neurology.
Headquartered in Burlington, N.C., Laboratory Corporation of America Holdings is a national clinical laboratory organization, which operates facilities for conducting clinical assays and diagnostic testing throughout the U.S. The company had 2000 revenues of $1.9 billion and employs approximately 18,000.
Charles River Laboratories International, Inc. (Charles River) is a global provider of solutions that advance the drug discovery and development process, including research models and associated services, and outsourced preclinical services. It provides the animal research models required in research and development for drugs, devices and therapies. Charles River’s customer base includes global pharmaceutical companies, a range of biotechnology companies, as well as government agencies, hospitals and academic institutions worldwide. It operates approximately 60 facilities, including its production and warehousing facilities, in 15 countries worldwide. The Company has two segments: Research Models and Services and Preclinical Services, which includes Phase I clinical services. In September 2008, Charles River announced that it has completed the acquisition of privately held NewLab BioQuality AG. In September 2008, Charles River acquired Molecular Imaging Research, Inc.
BioReliance Corporation is established as the parent Company to all testing, development and manufacturing subsidiaries worldwide. BioReliance completes its Initial Public Offering (IPO) effective August 1 and begins trading on the NASDAQ National Market under the symbol "BREL." Underwriters are Morgan Stanley and Hambrecht & Quist. The Company is awarded a five-year, $18 million NIEHS contract involving the evaluation of transgenic animal models for accelerated cancer risk assessment. Company scientists begin an effort to shorten the "in life" portion of long-term carcinogenicity studies from two years to six months. The Company is awarded four NIH contracts totaling $3.5 million for vector development and manufacturing in support of a number of different gene therapy protocols. The Company forms BioReliance GmbH to provide development services in Heidelberg, Germany. The Company celebrates the 50th anniversary of its founding on September 24 by breaking ground for a new 50,000 square foot headquarters and laboratory facility located among its existing laboratory facilities in Rockville, Maryland.
Strategic Diagnostics Inc. (SDI) provides an array of products and services, including custom antibodies, catalog antibodies, bulk antibodies and associated bio-processing services. The Company is an outsourcing partner for production of monoclonal and polyclonal antibodies embedded in commercialized products offered by diagnostic and pharmaceutical companies. SDI serves the research, bio-technology, human diagnostic, animal diagnostic and pharmaceutical industries. In July 2007, the Company acquired United States distribution rights for the Lumitester PD-10N/LuciPac W system from Kikkoman. (Source: 10-K)
Dade Behring is the world's largest company dedicated solely to clinical diagnostics. It offers a wide range of products and systems designed to meet the day-to-day needs of laboratories, making it today's best resource in this field. The company is headquartered in Deerfield, Illinois, and has operations in 43 countries.
SGS, headquartered in Geneva, Switzerland, is the global leader in the inspection, verification, testing and certification industry. SGS operates globally under the SGS brand. SGS operates a network comprised of more than 1,000 offices and laboratories and 37,000 employees with a presence in well over 120 countries.
Covance Inc. is a drug development services company providing a range of early-stage and late-stage product development services on a worldwide basis primarily to the pharmaceutical, biotechnology and medical device industries. The Company also provides laboratory testing services to the chemical, agrochemical and food industries. Covance maintains offices in more than 20 countries. The services it provides constitute two segments: early development services, which include preclinical services and clinical pharmacology services, and late-stage development services, which include central laboratory, clinical development, periapproval and market access services. Covance Inc. provides product development services on a global basis to, among others, the pharmaceutical and biotechnology industries. During the year ended December 31, 2007, the Company served in excess of 300 biopharmaceutical companies. (Source: 10-K)
Intertek is the leading international provider of quality and safety services to a wide range of global and local industries. Our services take us into almost every field imaginable, such as textiles, toys, electronics, building, heating, pharmaceuticals, petroleum, food and cargo scanning. We operate a global network of laboratories and offices with over 20,000 people in more than 100 countries around the world. Customers of Intertek include some of the world’s leading brands, major global and local companies and governments. Learn more at www.intertek.com.
Pharmaceutical Product Development, Inc. (PPD) is a global contract research organization engaged in providing drug discovery and development services, post-approval expertise and compound partnering programs. The Discovery Sciences Group focuses on the discovery research segment of the biopharmaceutical research and development outsourcing market. The Development Group has designed its various global services to be integrated in order to assist its clients in optimizing their research and development spending through the clinical stages of the development process. The Development Group provides a range of development services to meet clients' needs. In addition, for marketed drugs, biologics and devices, PPD offers support services, such as product launch services, medical information, patient compliance programs, patient and disease registry programs, product safety and pharmacovigilance, Phase IV monitored studies and prescription-to-over-the-counter programs. (Source: 10-K)
Beckman Coulter, Inc. is a manufacturer of biomedical testing instrument systems, tests and supplies that simplify and automate laboratory processes. Its products are used in a range of applications, from lab solutions used for pioneering medical research, clinical research and drug discovery to diagnostic systems found in hospitals and physicians’ offices to aid in patient care. The Company markets its products in more than 130 countries. During the year ended December 31, 2007, approximately 48% of revenue of the Company came from outside the United States. The Company has four product areas: Chemistry Systems, Immunoassay Systems, Cellular Systems, and Discovery and Automation Systems. On December 28, 2007, the Company acquired the flow cytometry instrument business of Dako Denmark A/S. (Source: 10-K)
Privacy Policy | Terms and Conditions | Do Not Sell My Personal Information | Websites Directory
Copyright © 2022 kwtbox.com. All Rights Reserved. US Business Directory